Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Dose-response Relationship of Five Dose Levels of NNC90-1170 and Placebo on Glycaemic Control in Type 2 Diabetic Patients Compared to OHA Treatment. A 12-week Multi-centre, Double-blind, Randomised, Parallel Group Trial With an Open Labelled OHA Arm

This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.

Inclusion Criteria:

• Subjects with type 2 diabetes
• Duration of diabetes at least 3 months
• Both diet treated and patients in therapy with OHA (oral hypoglycemic agents)
• Body Mass Index maximum 40 kg/m^2
• HbA1c based on analysis from central laboratory: Between 7.5-10.0%, both inclusive, for diet treated, or maximum 9.0% for OHA treated

Exclusion Criteria:

• Liver or renal disease
• Cardiac problems
• Uncontrolled treated/untreated hypertension
• Proliferative retinopathy
• Recurrent severe hypoglycaemia as judged by the Investigator
• Known or suspected allergy to trial product or related products
• Use of any drug (except for OHAs) which in the Investigator's opinion could interfere with the blood glucose level